ALK and anaplastic large cell lymphoma: OS data were available for 257 sALCL patients, these indicating a favorable prognosis associated with DUSP22R (5-year OS of 95%) and ALK+ ALCL (87%), an intermediate prognosis for TN cases, and a poor prognosis for TP63R and DH patients (0%).